Drug-Metabolizing Enzyme Genotypes and Aggressive Behavior Treatment Response in Hospitalized Pediatric Psychiatric Patients
- 1 August 2009
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 19 (4) , 385-394
Abstract
The aim of this study was to examine the association between the CYP2D6 and CYP2C19 genotype-predicted combined phenotypes and short-term measures of psychotropic efficacy and toxicity. A rater-blinded, retrospective genotype association design examined a cohort of hospitalized pediatric psychiatric patients genotyped for CYP2D6 and CYP2C19 as part of clinical care. These combined genotypes were used to predict a combined phenotype. The primary efficacy outcome measure was the behavior intervention score (BIS), a function of the number of recorded timeouts/seclusions, therapeutic holds, and physical restraints. Drug tolerability was defined as the total number of recorded adverse drug reactions. Primary analysis was performed on 279 pediatric patients taking CYP2D6- or CYP2C19- dependent psychotropics. Combined phenotype was associated with BIS (p = 0.01) and number of adverse drug reactions (p = 0.03). Combined poor metabolizers treated with psychotropics had the lowest BIS (highest efficacy) and the highest number of adverse drug reactions. Combined ultrarapid metabolizers had the highest BIS (lowest efficacy) and the lowest number of adverse drug reactions. Common variants in CYP2D6 and CYP2C19 are associated with the short-term efficacy and tolerability of psychotropic medications in hospitalized pediatric patients.Keywords
This publication has 30 references indexed in Scilit:
- Treatment for Adolescents With Depression Study (TADS)Journal of the American Academy of Child & Adolescent Psychiatry, 2006
- CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testingThe Pharmacogenomics Journal, 2006
- Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical ImplicationsThe Oncologist, 2006
- Pharmacogenomics and antidepressant drugsAnnals of Medicine, 2006
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- A Prospective Study of Assault Against Staff by Youths in a State Psychiatric HospitalPsychiatric Services, 2004
- Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseMolecular Psychiatry, 2004
- Ultrarapid metabolizers of debrisoquine: Characterization and PCR‐based detection of alleles with duplication of the CYP2D6 geneFEBS Letters, 1996
- Development of health risk appraisal functions in the presence of multiple indicators: The Framingham Study nursing home institutionalization modelStatistics in Medicine, 1995
- A Weight-Free Index for the Purpose of Ranking or Selection with Respect to Several Traits at a TimeBiometrics, 1963